Table 2.
The main characteristics of the mushroom lipid raft binding proteins.
| Protein | KD (nM; SM/Chol) | Co-Localization | Cell Model | Biotechnological Applications | Reference |
|---|---|---|---|---|---|
| OlyA | >1000 | / | Lipid raft biomarker | [36,41,45] | |
| OlyA6 | ND | Caveolin 1 | MDCK cells | Lipid raft biomarker; OlyA6-induced vesicles for sampling of cytoplasm or as model plasma membrane vesicles; tool for delivering pharmacologically active substances to specific intracellular compartments; treatment of bladder cancer (with PlyB) | [37,42,46,47] |
| rOly | ND | ND | ND | Treatment of colorectal tumors and metabolic disorders | [43,48,49] |
| PlyA | ND | ND | ND | Lipid raft biomarker | [50] |
| PlyA2 | >1000 | CD59 | Hela cells | Lipid raft biomarker | [38] |
| Nakanori | 141 | Lysenin; BMP/LBPA; CD63; Lamp1 | Hela cells | Lipid raft biomarker; tool for detecting alterations in membrane dynamics (detection of Niemann–Pick disease); inhibition of release of influenza virus from MDCK cells | [40] |
KD dissociation constant; MDCK, Madin-Darby Canine Kidney (cells); ND, not determined.